Androgen Suppression and Radiation With/Out Docetaxel in High-Risk Localized Prostate Cancer
Androgen Suppression and Radiation With/Out Docetaxel in High-Risk Localized Prostate Cancer
RATIONALE: Androgens can cause the growth of prostate cancer cells. Antihormone therapy, such
 as flutamide, bicalutamide, leuprolide, buserelin, and goserelin, may lessen the amount of
 androgens made by the body. Radiation therapy uses high-energy x-rays to kill tumor cells.
 Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of
 tumor cells, either by killing the cells or by stopping them from dividing. It is not yet
 known whether giving androgen suppression therapy together with radiation therapy is more
 effective with or without docetaxel in treating prostate cancer.

 PURPOSE: This randomized phase III trial is studying androgen suppression therapy, radiation
 therapy, and docetaxel to see how well they work compared with androgen suppression therapy
 and radiation therapy in treating patients with high-risk localized prostate cancer.

 CLOSURE: This trial closed to further accrual in November 2009. The study endpoints will not
 be reached.
OBJECTIVES:

 Primary

 -  To compare disease-free survival rates in patients with high-risk localized
 adenocarcinoma of the prostate treated with androgen suppression therapy and
 radiotherapy with vs without docetaxel.

 Secondary

 -  To compare overall survival.

 -  To compare time to biochemical disease progression.

 -  To compare time to local disease progression.

 -  To compare time to distant disease progression.

 -  To compare time to next anticancer therapy.

 -  To compare progression-free survival.

 -  To compare degree of prostate-specific antigen (PSA) suppression prior to radiotherapy.

 -  To compare quality of life (QOL) using EORTC QLQ C30 and EORTC QLQ PR25 questionnaires
 and a trial-specific checklist.

 -  To compare the nature, severity, and frequency of adverse events.

 OUTLINE: This is a multicenter study. Patients are stratified according to Gleason score (≤ 7
 vs ≥ 8), baseline prostate-specific antigen (PSA) (> 20 ng/mL vs ≤ 20 ng/mL), and
 participating center. Patients are randomized to 1 of 2 treatment arms.

 -  Arm I: Patients receive androgen suppression therapy comprising oral flutamide three
 times daily or oral bicalutamide once daily for 4 weeks AND leuprolide subcutaneously
 (SC) or intramuscularly every 1-6 months, buserelin SC every 2 or 3 months, or goserelin
 SC every 1 or 3 months for 3 years. Patients also receive docetaxel IV over 60 minutes
 on day 1. Treatment with docetaxel repeats every 21 days for up to 4 courses. Beginning
 at least 4 weeks after completion of chemotherapy, patients undergo pelvic radiotherapy
 once daily 5 days a week for up to 8 weeks.

 -  Arm II: Patients receive androgen suppression therapy and undergo pelvic radiotherapy as
 in arm I.

 Patients complete quality of life questionnaires at baseline, periodically during treatment,
 and then every 6 months for 5 years.

 After completion of study treatment, patients are followed at 3 and 6 months, every 6 months
 for 5 years, and then annually thereafter.
DISEASE CHARACTERISTICS:

 -  Histologically confirmed adenocarcinoma of the prostate

 -  Localized (N0, M0) disease

 -  No small cell or transitional cell carcinoma in the biopsy specimen

 -  Considered to be at high risk for recurrence based on the presence of at least one of
 the following adverse prognostic features:

 -  T stage ≥ 3a

 -  Gleason score ≥ 8

 -  Baseline prostate-specific antigen (PSA) > 20 ng/mL

 -  Deemed to be an appropriate candidate for chemotherapy, as assessed by a medical
 oncologist

 -  Negative pelvic and para-aortic lymph nodes on CT scan or MRI of the abdomen and
 pelvis

 -  Any lymph node appearing ≥ 1.5 cm on CT scan or MRI must be histologically
 negative by either needle aspirate or lymph node dissection

 -  No metastases by chest x-ray and bone scan

 PATIENT CHARACTERISTICS:

 -  ECOG performance status 0-1

 -  Absolute neutrophil count ≥ 1,500/mm³

 -  Platelet count ≥ 100,000/mm³

 -  Hemoglobin ≥ 10.0 g/dL

 -  AST and/or ALT ≤ 1.5 times upper limit of normal (ULN)

 -  Alkaline phosphatase ≤ 2.5 times ULN

 -  Total bilirubin normal

 -  Serum creatinine ≤ 1.5 times ULN

 -  Able (i.e., sufficiently fluent) and willing to complete the quality of life
 questionnaires in either English or French

 -  Fertile patients must use effective contraception

 -  No history of other malignancies, except adequately treated nonmelanoma skin cancer or
 other curatively treated solid tumor with no evidence of disease for > 5 years

 -  No serious non-malignant disease resulting in a life expectancy of < 10 years

 -  No known hypersensitivity to any study medications

 -  No existing peripheral neuropathy ≥ grade 2

 -  No bilateral hip replacement prostheses

 -  No contraindication to pelvic radiotherapy including, but not limited to, inflammatory
 bowel disease or severe bladder irritability

 -  No medical condition that would contraindicate the study treatment regimen, including
 severe respiratory insufficiency, uncontrolled diabetes, or severe hypertension

 -  No other serious illness or psychiatric or medical condition that would preclude
 management of the patient according to the study, including active uncontrolled
 infection or significant cardiac dysfunction

 PRIOR CONCURRENT THERAPY:

 -  Prior androgen suppression therapy allowed provided it was initiated no more than 4
 weeks prior to study entry

 -  At least 4 weeks since prior 5-alpha-reductase inhibitors (e.g., finasteride) for
 benign prostatic hypertrophy

 -  No prior cytotoxic anticancer therapy

 -  No prior chemotherapy for carcinoma of the prostate

 -  No prior surgical treatment for carcinoma of the prostate, except transurethral
 resection or bilateral orchiectomy

 -  No prior pelvic radiotherapy

 -  No concurrent nilutamide

 -  No other concurrent investigational drugs

 -  No other concurrent anticancer therapy (cytotoxic therapy, biologic/immunotherapy, or
 radiotherapy)